Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Master Regulatory Gene Network (MRGN) is a core regulatory state identified in glioblastoma (GBM), particularly within glioblastoma stem-like cells (GSCs). This network is restructured by founding mutations and maintained across various subclones, contributing to the profound heterogeneity and therapeutic resistance characteristic of GBM (Source 3.2.1, 5.3.1). The MRGN is anchored by developmentally restricted master regulators (MRs) that are essential for maintaining the GSC state and driving tumor growth (Source 3.2.2, 5.3.2). Therapeutic strategies targeting the MRGN utilize AI-directed identification (such as the NETZEN suite) to pinpoint key master regulators, which are then targeted using shRNA-based gene therapies delivered via viral vectors like adeno-associated virus (AAV) (Source 4.2.4, 5.2.2). By disrupting this core regulatory network, these therapies aim to force GSCs into a differentiated or apoptotic state, providing a heterogeneity-agnostic approach to treating glioblastoma (Source 3.2.1, 5.3.1).
shRNA-mediated knockdown of master regulators within the network to disrupt the oncogenic state and induce differentiation or cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Master Regulatory Gene Network (MRGN) (MRGN).